In the clinical trials, GLP-1 agonists like semaglutide have shown improvements in both weight loss and blood sugar regulation
Two phase 3 trials found better desire scores and lower distress than placebo
Our capabilities support global Phase IIIV programs with a focus on efficacy, long-term safety, and real-world evidence generation
Diabetes Diabetes is a leading cause of blindness, amputations, heart disease, kidney failure, and premature death
Persistent nausea, early satiety, bloating, or constipation may lead to reduced treatment satisfaction and contribute to therapy interruption or discontinuation
So, drugs that lead to substantial weight loss could be associated with a decrease in incidence of these obesity-related cancers